Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Maintenance Therapy With Oxytocin Antagonists for Inhibiting Preterm Birth After Threatened Preterm Labour." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437474/all/Maintenance_therapy_with_oxytocin_antagonists_for_inhibiting_preterm_birth_after_threatened_preterm_labour.
Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437474/all/Maintenance_therapy_with_oxytocin_antagonists_for_inhibiting_preterm_birth_after_threatened_preterm_labour. Accessed January 20, 2026.
Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437474/all/Maintenance_therapy_with_oxytocin_antagonists_for_inhibiting_preterm_birth_after_threatened_preterm_labour
Maintenance Therapy With Oxytocin Antagonists for Inhibiting Preterm Birth After Threatened Preterm Labour [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 January 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437474/all/Maintenance_therapy_with_oxytocin_antagonists_for_inhibiting_preterm_birth_after_threatened_preterm_labour.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
ID - 437474
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437474/all/Maintenance_therapy_with_oxytocin_antagonists_for_inhibiting_preterm_birth_after_threatened_preterm_labour
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -

Cochrane Abstracts

